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Letter to the 
editor
Clinical studies point towards an associa-
tion between periodontitis and rheumatoid 
arthritis (RA) [1, 2]. A pathogenic role is 
suggested for Porphyromonas gingivalis [3]. 
P. gingivalis may contribute to the pathoge-
nesis of RA by breaking immune tolerance 
through formation of (bacterial and human) 
citrullinated proteins, leading to anticitrul-
linated protein antibody production (ACPA) 
[4, 5]. Since ACPA production precedes RA 
development [7] and because P. gingivalis 
IgG antibodies are long-term stable in untre-
ated periodontitis patients [8], we investiga-
ted whether anti-P. gingivalis antibody levels 
are prognostic for development of RA, by 
assessing these antibodies in a cohort of 289 
adults at risk for RA. 
Patients with arthralgia and seropositivity for 
IgM rheumatoid factor (IgM RF) and/or ACPA 
were selected from a prospective follow-up 
study on arthritis development [9]. The oc-
currence of arthralgia in people with these 
autoantibodies probably represents a late 
stage in the preclinical development of (rheu-
matoid) arthritis, especially if the symptoms 
are symmetrically located in the small joints, 
a situation which could be named ‘inflam-
matory arthralgia’ [10]. They are further 
referred to as seropositive arthralgia patients 
(SAP); their median follow-up was 30 months 
(IQR 13–49). 
Baseline sera were used for measurement of 
ACPA, IgM RF, C-reactive protein (CRP) and 
HLA-DRB1 SE carrier status [9]. IgA, IgG and 
IgM antibody levels against P. gingivalis were 
determined by in-house ELISA with a pooled 
lysate of clinical isolates of P. gingivalis as 
antigen [11]. Interference of IgM RF on anti-
P. gingivalis antibody assays was excluded by 
spiking samples with sera with known high 
titres of RF. 
Reference groups for antibody levels against 
P. gingivalis consisted of healthy subjects 
without periodontitis and without cultivable 
subgingival P. gingivalis (HC, n = 36, mean 
age 34 ± 15 years, 53% female, 14% current 
smoker) and severe periodontitis patients 
without systemic disease (PD, n = 117, mean 
age 51 ± 9.3 years, 58% female, 43% current 
smoker, 42% of n = 45 P. gingivalis-culture 
positive [12]. Both groups were recruited 
among subjects planned for first consultation 
at the dental department of the University 
Medical Center Groningen and a referral 
practice for periodontology (Clinic for Perio-
dontology Groningen) [11].
IgA and IgG anti-P. gingivalis were higher in 
PD than in HC (both p < 0.0001). PD culture-
positive for subgingival P. gingivalis had 
higher IgA and IgG anti-P. gingivalis than 
culture-negative PD ( p < 0.01 and p < 0.001). 
No differences were found for IgM anti-P. 
gingivalis.
Cut-off values for anti-P. gingivalis positivity 
were set at >2 SD above the mean of HC. 
Influence of anti-P. gingivalis positivity on RA 
development was analyzed using a multiva-
riate Cox proportional hazards model with 
time until RA development as dependent 
variable and age, gender, HLA-DRB1 SE carri-
age, smoking, number of tender joints, and 
CRP- ACPA- and IgM RF-positivity at inclusion 
as other variables.
After 12 months (median, IQR 6–20), 33% (n 
= 94) of SAP had developed RA according to 
2010 American College of Rheumatology/Eu-
ropean League against Rheumatism criteria 
[13]. Baseline characteristics of SAP who 
developed RA (RA+) or did not develop RA 
(RA−) are listed in Table 1, page 50.
In SAP, IgG anti-P. gingivalis was higher than 
in HC, but lower than in PD, as was IgA anti-P. 
gingivalis (Fig. 1A, page 51). No differences 
in IgM anti-P. gingivalis were found, nor were 
differences found for anti-P. gingivalis anti-
body levels between ACPA-positive or ACPA-
negative SAP.
SAP who developed RA did not have elevated 
anti-P. gingivalis antibody levels at baseline 
compared with SAP who did not develop RA 
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within the follow-up period (Fig. 1B, page 
51). When using cut-off values for anti-P. gin-
givalis positivity, the proportion of IgA and 
IgG anti-P. gingivalis-positive patients was 
higher in SAP who did not develop RA (Table 
1, page 50). Besides a weak correlation of 
IgM anti-P. gingivalis with ACPA in SAP who 
developed RA (p < 0.05, ρ = 0.23), no other 
correlation with anti-P. gingivalis was found.
The multivariate Cox proportional hazards 
model showed significant influence of ACPA 
(HR 11, 95% CI 5.1 to 24, p < 0.0001), IgM RF 
(HR 2.5, 95% CI 1.6 to 4.1, p < 0.0001), num-
ber of tender joints (HR 1.05, 95% CI 1.01 to 
1.09, p < 0.05) and HLA-DRB1 SE carriage (HR 
1.7, 95% CI 1.1 to 2.6, p < 0.05) on RA deve-
lopment. Influence of anti-P. gingivalis, CRP, 
age, gender and smoking could not be esta-
blished. Within the limitations of this study, 
we conclude that anti-P. gingivalis antibody 
levels are not prognostic for development of 
RA.
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Table 1 Baseline characteristics of seropositive arthralgia patients (SAP) who did (RA+) or did 
not (RA−) develop rheumatoid arthritis within the follow-up period 
 All SAP RA+ RA- P value RA+ vs. 
RA- 
Number 289 94 195  
Female, percentage 79 81 78 0.76 
Mean age in years (SD) 50 (12) 48 (11) 50 (12) 0.19 
Smoking at inclusion, percentage 29 35 26 0.13 
HLA-DRB1 SE, percentage 40 45 37 0.19 
Seropositive for IgM-RF, percentage 61 57 63 0.37 
Seropositive for IgG ACPA, percentage 65 90 53 0 







Median (IQR) TJC53 at inclusion  0 (0-3) 1 (0-4) 0 (0-3) 0.1 
Median (IQR) follow-up in months  30 (13-49) 25 (12-46) 34 (15-49) 0.05 
Median (IQR) time until RA development - 12 (6-20) - - 
Positive for anti- P. gingivalis IgA, 
percentage† 
20 11 25 0.01 
Positive for anti- P. gingivalis IgG, 
percentage† 
34 26 37 0.05 
Positive for anti- P. gingivalis IgM, 
percentage† 
6.9 5.3 7.7 0.62 
*Variables reflected in percentages: Fisher’s exact test with two sided p value, other variables: unpaired t-test 
with Welch’s correction (Gaussian distribution) or Mann–Whitney U test (no Gaussian distribution).  
†Positivity is defined as >2 SD above the mean anti-P. gingivalis levels of healthy controls. ACPA anti-
citrullinated protein antibodies, cut-off level for positivity 5 U/mL, HLA-DRB1 SE one or two copies of the HLA-
DRB1*0101, *0102, *0401, *0404, *0405, *0408, *0410 or *1001 alleles, hsCRP, high-sensitivity C-reactive 
protein, RA rheumatoid arthritis, RF rheumatoid factor, cut-off level for positivity 30 IU/mL, TJC53 tender joint 
count 53 joints. 
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DRB1*0101, *0102, *0401, *0404, *0405, *0408, *0410 or *1001 alleles, hsCRP, high-sensitivity C-reactive 
protein, RA rheumatoid arthritis, RF rheumatoid factor, cut-off level for positivity 30 IU/mL, TJC53 tender joint 
count 53 joints. 
 
Table 1 Baseline characteristics of seropositive arthralgia patients (SAP) who did (RA+) or did 
not (RA−) develop rheumatoid arthritis within the follow-up period.
*Variables reflected in percentages: Fisher’s exact test with two sided p value, other variables: 
unpaired t-test with Welch’s correction (Gaussian distribution) or Mann–Whitney U test (no 
Gaussian distribution). 
†Positivity is defined s >2 SD above the mean anti-P. gingivalis le els of healthy controls. 
ACPA: anti-citrullinated protein antibodies, cut off level for positivity 5 U/mL, HLA-DRB1 SE: 
one or two copies of the HLA-DRB1*0101, *0102, *0401, *0404, *0405, *0408, *0410 or 
*1001 alleles, hsCRP: high-sensitivity C-reactive protein, RA: rheumatoid arthritis, RF: rheuma-
toid factor, cut off level for positivity 30 IU/mL, TJC53: tender joint count 53 joints.
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Fig. 1 (A) IgA, IgG and IgM anti-Porphyromonas gingivalis antibody levels in seropositive 
arthralgia patients (SAP) compared with severe periodontitis patients without other systemic 
disease and healthy controls with a healthy periodontium and no cultivable subgingival P. 
gingivalis (HC). (B) IgA, IgG and IgM anti-P. gingivalis antibody levels in SAP who developed 
rheumatoid arthritis (RA+) and SAP who did not develop rheumatoid arthritis (RA−) according 
to the 2010 American College of Rheumatology (ACR)/European League against Rheumatism 
(EULAR) criteria. 
Solid lines represent median values. Dotted lines indicate arbitrary cut-off values for anti-P. 
gingivalis positivity defined as >2 SD above the mean of the healthy controls. 
Comparison of three groups: Kruskal-–Wallis one-way analysis of variance with Dunn’s multi-
ple comparison post-test if overall p < 0.05. Comparison of two groups: Mann–Whitney U test 
with two-sided p value. *p < 0.05, **p < 0.001.
Chapter 3: Antibodies against Porphyromonas gingivalis in seropositive arthralgia patients do not 
predict development of rheumatoid arthritis
51
Fig. 1 (A) IgA, IgG and IgM anti-Porphyromonas gingivalis antibody levels in seropositive 
arthralgia patients (SAP) compared with severe periodontitis patients without other systemic 
disease and healthy controls with a healthy periodontium and no cultivable subgingival P. 
gingivalis (HC). (B) IgA, IgG and IgM anti-P. gingivalis antibody levels in SAP who developed 
rheumatoid arthritis (RA+) and SAP who did not develop rheumatoid arthritis (RA−) according 
to the 2010 American College of Rheumatology (ACR)/European League against Rheumatism 
(EULAR) criteria. 
Solid lines represent median values. Dotted lines indicate arbitrary cut-off values for anti-P. 
gingivalis positivity defined as >2 SD above the mean of the healthy controls. 
Comparison of three groups: Kruskal-–Wallis one-way analysis of variance with Dunn’s multi-
ple comparison post-test if overall p < 0.05. Comparison of two groups: Mann–Whitney U test 
with two-sided p value. *p < 0.05, **p < 0.001.
Chapter 3: Antibodies against Porphyromonas gingivalis in seropositive arthralgia patients do not 
predict development of rheumatoid arthritis
52 52
